Effect of Transjugular Intrahepatic Portosystemic Shunt for Variceal bleeding in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.
- Author:
Woo Jin CHUNG
1
;
Byung Kuk JANG
;
Kyung Sik PARK
;
Kwang Bum CHO
;
Jae Seok HWANG
;
Sung Hun AHN
;
Yong Hoon KIM
;
Young Hwan KIM
;
Yong Ju KIM
Author Information
1. Department of Internal Medicine, Surgery, Keimyung University College of Medicine, Daegu, Korea. chung50@dsmc.or.kr
- Publication Type:Original Article ; English Abstract
- Keywords:
TIPS;
Variceal bleeding;
Hepatocellular carcinoma;
Portal vein thrombosis
- MeSH:
Adult;
Carcinoma, Hepatocellular/*complications;
English Abstract;
Esophageal and Gastric Varices/complications/*therapy;
Gastrointestinal Hemorrhage/*therapy;
Humans;
Liver Neoplasms/*complications;
Male;
Middle Aged;
*Portal Vein;
*Portasystemic Shunt, Transjugular Intrahepatic;
Venous Thrombosis/*complications
- From:The Korean Journal of Hepatology
2005;11(2):157-163
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Transjugular Intrahepatic Portosystemic Shunt (TIPS) is commonly used in patients with variceal bleeding. However, this procedure is contraindicated in hepatocellular carcinoma patients with portal vein thrombosis. This study was done to evaluate the effect of TIPS in those patients with variceal bleeding. METHODS: Between 1997 and 2004, six hepatocellular carcinoma (HCC) patients with portal vein thrombosis were enrolled in this study due to their variceal bleeding. All the patients underwent TIPS placement to treat the variceal bleeding that had not responded to endoscopic treatment. Effective shunt creation was assessed by the decrease of the portal pressure gradient (less than 12 mmHg) or if good patency and flow were seen on a doppler examination. RESULTS: Shunts were successfully created in all the patients and the bleeding was immediately controlled in the active bleeding cases. The bleeding was caused by esophageal varices in one patient and, by gastric varices in five patients. The HCC types were diffuse or massive in five patients, and a single nodule was present in one patient. All the patients had portal vein thrombosis. Rebleeding was noted in two patients at 10 days and 3 months, respectively, due to the shunt occlusion. Hepatic encephalopathy was noted in two patients. The causes of death were hepatorenal syndrome after 2 weeks in one patient, bleeding due to portal hypertensive gastropathy after 3 weeks in another, and cancer progression after 4 months in third patient. CONCLUSIONS: For HCC patients with portal vein thrombosis, TIPS can be an effective treatment modality if uncontrolled variceal bleeding presents when using endoscopic hemostasis or pharmacologic therapy. However, further studies are needed.
